Japan’s Market Expansion Rule Going Nowhere, But Hope Remains For Pricing Premium
This article was originally published in PharmAsia News
Executive Summary
Eli Lilly’s John Lechleiter and Alfonso Zulueta, as representatives from PhRMA, pressed the Japanese government to make permanent a temporary program that benefits innovative products. PhRMA believes the “market expansion rule" is a disincentive compared to the premium pricing given for innovative products.